C3.ai Digital Transformation Institute Announces Call for Papers to Advance AI for Energy and Climate Security
2.2.2021 14:00:00 EET | Business Wire | Press release
The C3.ai Digital Transformation Institute invites scholars, software developers, and researchers to address the challenge of re-envisioning energy systems with artificial intelligence (AI) and digital transformation to lead the way to a lower-carbon, higher-efficiency economy that will enhance both energy and climate security.
“Mitigating the impact of global energy generation will require a massive transformation of the world’s energy infrastructure,” said Thomas M. Siebel, chairman and CEO of C3 AI, a leading enterprise AI software provider for accelerating digital transformation. “This call for proposals covers topics that aim to provide safer, cleaner, lower cost, and more reliable energy through the application of AI.”
Immediate Call for Proposals : AI and Digital Transformation for Energy and Climate Security.
Topics for research awards may include, but are not limited to, the following:
-
Sustainability: Applying AI, machine learning, and advanced analytic techniques to support sustainability initiatives for energy consumption and greenhouse gas emissions
-
AI for Carbon Sequestration: Applying AI/ML techniques to increase the scale and reduce the cost of carbon sequestration
-
AI for Leaks and Emissions Detection: Applying advanced AI/ML techniques for large-scale emissions detection, facility-level data reconciliation and gap analysis for emissions sensors, prediction of emissions risk, and analysis and optimization of flaring intensity across upstream and downstream operations
-
Safe Hydrocarbon Production and Transportation Infrastructure: Applying analytic and AI/ML modeling techniques to increase the safety and reduce emissions from oil and gas extraction, petrochemical production, and hydrocarbon transportation
-
AI for Advanced Energy and Carbon Markets: Enabling dynamic, automated, and real-time pricing of energy generation sources
-
Cybersecurity of Power and Energy Infrastructure: Leveraging AI/ML techniques to improve the cybersecurity of our critical power and energy assets, as well as smart connected factories and homes
-
Smart Grid Analytics: Applying AI and other analytic approaches to improve the efficiency and effectiveness of grid transmission and distribution operations
-
Distributed Energy Resource Management: Applying AI to increase the penetration and use of distributed renewables
-
AI for Energy-Efficient Buildings and Factories: Leveraging AI techniques for advanced building and factory control to improve energy efficiency
-
AI for Improved Natural Catastrophe Risk Assessment: Applying AI to improve modeling of natural catastrophe risks from future weather-related events (e.g., tropical storms, wildfires, and floods)
-
Resilient Energy Systems: Addressing how the use of AI/ML techniques and markets for energy and carbon introduce new vulnerabilities
- AI for Improved Climate Change Modeling: Use of AI/ML to address climate change modeling and adaptation
“The energy industry is at a critical inflection point to accelerate delivery of cleaner, safer energy while meeting growing demand,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes, an energy technology company serving energy and industrial customers worldwide. “We are excited about our partnership with the C3.ai Digital Transformation Institute and the impact these funded research projects will have in advancing AI at scale for the energy transition.”
This second call for proposals is open now, with a submission deadline of March 29, 2021. Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai. Selected proposals will be announced in mid-May, with start dates of June 1, 2021.
Up to $5 million in cash awards will be funded from this second call, ranging from $100,000 to $250,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3 AI. This will include unlimited use of the C3 AI® Suite, access to the Microsoft Azure cloud platform, and access to the Blue Waters supercomputer at the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign.
Establishing the New Science of Digital Transformation
C3.ai DTI focuses its research on AI, machine learning, IoT, big data analytics, human factors, organizational behavior, ethics, and public policy. The Institute supports the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research analyzes new business operation models, develops methods of implementing organizational change management and protecting privacy, and amplifies the dialogue around the ethics and public policy of AI.
About C3.ai Digital Transformation Institute
C3.ai Digital Transformation Institute represents an innovative vision to take AI, ML, IoT, and big data research in a consortium model to a level that cannot be achieved by any one institution alone. Jointly managed and hosted by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI attracts the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new science of digital transformation. To support the Institute, C3 AI will provide $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005323/en/
Contact information
C3.ai DTI Contact:
Kap Stann
Communications Manager, C3.ai DTI @ Berkeley
Tel. +1 510-295-9685
Kstann@berkeley.edu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
